JD
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study | Transplant Infectious Disease | 2020 | 400 | 2 | |||
| A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa | Science Translational Medicine | 2017 | 629 | 2 | |||
| Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey | PLOS ONE | 2017 | 500 | 194 | |||
| Clinical Management of Ebola Virus Disease in the United States and Europe | New England Journal of Medicine | 2016 | 1,217 | 340 | |||
| Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report | The New England journal of medicine | 2016 | 917 | 262 | |||
| Ebola Virus Disease Complications as Experienced by Survivors in Sierra Leone | Clinical infectious diseases | 2016 | 636 | 418 | |||
| The 2014–2015 Ebola outbreak in West Africa: Hands On | Antimicrobial Resistance and Infection Control | 2016 | 536 | 226 | |||
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial | Lancet. Infectious diseases | 2015 | 699 | 0 | |||
| Ebola: le point au crépuscule d'une épidémie inattendue | Revue médicale suisse | 2015 | 136 | 120 | |||
| Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report | Lancet. Infectious diseases | 2015 | 706 | 1 |
